Sagimet Biosciences Inc. Class A SGMT 深 沪
交易中 05-11 11:36:50 美东时间
7.85
+0.160
+2.08%
华盛通- 最 高8.38
- 今 开7.70
- 成交量 27.25万股
- 最 低 7.47
- 昨 收 7.69
- 总市值 0
- 52周最高 11.41
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 3.15
- 委 比 -9.59%
- 总股本 --
- 历史最高 20.71
- 量 比 0.90
- 振 幅 11.83%
- 历史最低 1.73
- 每 手 1
- 风险率 1.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sagimet to Share Mid-Stage Liver Disease Drug Data at Medical Conference
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an
04-06 19:09
歌礼制药-B(01672)与国家药监局完成地尼法司他(ASC40)的新药上市申请前沟通
歌礼制药-B(01672)发布公告，公司董事会宣布，已于近期与中国国家药品监督管理局就地尼法司他(denifanstat，ASC40)治疗中重度寻常性痤疮完成新...
2025-10-14 17:55
歌礼制药-B(01672.HK)正与国家药监局进行地尼法司他的上市申请前沟通
【财华社讯】歌礼制药-B(01672.HK)公布，在2025年9月17日于法国巴黎举行的2025年欧洲皮肤病与性病学会(EADV)年会最新突破性研究专场上口...
2025-09-18 09:55
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
Sagimet Biosciences will host a virtual KOL event on June 16, 2025, featuring Neal Bhatia, MD, to discuss positive results from a Phase 3 trial of denifanstat for moderate to severe acne vulgaris in China. Denifanstat, a daily oral FASN inhibitor, met all endpoints versus placebo and showed strong tolerability, highlighting FASN inhibition as a novel acne treatment. The company also initiated a Phase 1 trial for TVB-3567, its second FASN inhibitor targeting acne in the U.S.
2025-06-09 11:00
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat successfully met all endpoints in Phase 3 trials for moderate-to-severe acne, with a novel FASN inhibitor entering Phase 1 studies.
2025-06-04 09:00
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
Sagimet Biosciences will host a virtual event on May 29, 2025, to discuss the potential of combining denifanstat and resmetirom for treating advanced MASH, based on positive Phase 2b trial results and preclinical synergistic data.
2025-05-22 12:00
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
2025-03-12 01:03
国产痤疮药在美注册上市，竞品最低售价超500美元，艾棣维欣发力OTC缓解资金焦虑？
行至2024年年末，痤疮药物赛道迎来新的竞争者。 近日，艾棣维欣（苏州）生物制药有限公司（874055.NQ，下称“艾棣维欣”）的可溶性微针OTC药品已获得美国...
2024-12-31 16:14
